India, Aug. 26 -- Viva Biotech Holdings Group (1873.HK) reported interim results for the six months ended June 30, 2026, with revenue rising 21 percent year over year, driven primarily by growth in Langhua Pharmaceutical's CDMO business and the advancement of commercial manufacturing projects.
Revenue totaled RMB1.01 billion, up from RMB831.9 million in the prior-year period, while gross profit increased 0.7 percent to RMB341.7 million from RMB339.4 million.
Gross profit margin was 34.0 percentfor the first half of 2026, compared with 40.8 per cent in the prior-year period.
Net profit totaled RMB100.9 million, down from RMB148.6 million in the First Half of 2025.
Adjusted non-IFRS net profit was RMB128.3 million, compared with RMB183.5 ...